IBRX270115P00015000
IBRX Jan 15 2027 15.00 Put
optionOPRA
EODOct 15, 2026
7.70USD+21.835%(+1.38)1Vol503OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
15
Expiration
Jan 15, 2027
DTE
87d
Moneyness
ITM
Intrinsic
$6.52
IBRX 15 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | $5.70 | +7.55% | 2 | 2 |
| Nov 6, 2026 | 17d | $5.27 | +7.11% | 2 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $7.70 | +21.84% | 1 | 503 |
| Mar 19, 2027 | 150d | $7.90 | -8.14% | 3 | 5 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | $8.20 | +7.47% | 1 | 6 |
| Aug 20, 2027 | 304d | $9.15 | +0.00% | 2 | 2 |
| Nov 19, 2027 | 395d | $8.53 | +3.39% | 1 | 2 |
| Jan 21, 2028 | 458d | $7.25 | -14.71% | 1 | 676 |
| Mar 17, 2028 | 514d | $8.50 | -5.56% | 1 | 19 |
| Jan 19, 2029 | 822d | $8.75 | +0.00% | 7 | 7 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 9 P | $1.62 | +5.88% | 72 | 52,470 | ITM |
| 10 P | $2.06 | +1.48% | 50 | 6,506 | ITM |
| 11 P | $2.65 | -7.02% | 7 | 150 | ITM |
| 12 P | $3.30 | -10.81% | 4 | 881 | ITM |
| 13 P | $4.70 | +14.63% | 2 | 6 | ITM |
| 14 P | $4.80 | -9.60% | 20 | 24 | ITM |
| 15 P | $7.70 | +21.84% | 1 | 503 | ITM |
| 16 P | $6.94 | +1.61% | 5 | 346 | ITM |
| 17 P | $7.75 | +2.24% | 56 | 92 | ITM |
| 18 P | $8.75 | +3.06% | 8 | 18 | ITM |
| 20 P | $11.40 | -13.64% | 20 | 23 | ITM |
| 22 P | $11.97 | -9.32% | 31 | 43 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.